Shots:

• The P-III JUNIPERA study assesses the efficacy and safety of secukinumab (75 /150 mg) vs PBO in 86 children and adolescents aged 2-17yrs. with a confirmed diagnosis of JPsA or ERA (subtype of JIA)
• The study met its 1EPs i.e delayed time to flare and demonstrates efficacy with more patients achieving and maintains the JIA ACR 30 and JIA ACR 70 responses @12 to 104 wks.- favorable safety profile with no new safety signals were identified with 2yrs. treatment
• The regulatory submissions in the EU and the US are expected in the coming wks. The therapy has received EU and US approval as a 1L systemic treatment for pediatric psoriasis

  Ref: Novartis | Image: Novartis